Francois Nader

Type: Person

Name: Francois Nader

First reported 6 hours ago - Updated 6 hours ago - 1 reports

NPS Pharmaceuticals Q1 net loss decreases

NPS Pharmaceuticals, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $7.80 million, or $0.09 loss per share, compared to a net loss of $10.56 million, or $0.12 loss per share, for the same quarter ... [Published Individual.com - 6 hours ago]

Entities: NPS Pharmaceuticals Inc, Hypoparathyroidism, Francois Nader, Teduglutide, GATTEX

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Ernst & Young

NPS Pharmaceuticals CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Year 2013

Dr. Francois NaderBEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, announced that president ... [Published Citybizlist - May 16 2013]

Entities: Ernst & Young, NPS Pharmaceuticals Inc, Francois Nader, Entrepreneur

First reported May 09 2013 - Updated May 09 2013 - 2 reports

NPS Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

8:30 AM ETOperatorGood day, ladies and gentlemen, and welcome to the First Quarter 2013 NPS Pharmaceuticals Earnings Conference Call. (Operator Instructions). As a reminder this conference is being recorded for replay purposes.I’d now like to turn the ... [Published Seeking Alpha - May 09 2013]

Entities: GATTEX, Short Bowel Syndrome, Patient, Hypoparathyroidism, NPS Pharmaceuticals Inc

First reported Mar 19 2013 - Updated Mar 19 2013 - 1 reports

NPS Pharmaceuticals and Takeda Revise Agreements (Transcript)

NPS Pharmaceuticals Inc. ( NPSP ) NPS Pharmaceuticals and Takeda Revise Agreements Conference Call March 19, 2013 8:30 AM ET Executives Susan Mesco – Corporate Communications Francois Nader – President and CEO Eric Pauwels – SVP and Chief Commercial ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 19 2013]

Entities: NPS Pharmaceuticals Inc, Francois Nader, David Friedman, Alan Carr, Pauwels

First reported Mar 13 2013 - Updated Mar 14 2013 - 1 reports

Barclays Capital Inc

NPS Pharmaceuticals' CEO Presents at Barclays Capital Global Healthcare Conference (Transcript)

NPS Pharmaceuticals Inc. ( NPSP ) Barclays Capital Healthcare Conference Call March 13, 2013 11:15 AM ET Executives Francois Nader – President and CEO Analysts Christine Cho – Barclays Capital Presentation Christine Cho – Barclays ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 13 2013]

Entities: NPS Pharmaceuticals Inc, Barclays Capital Inc, Healthcare Conference

First reported Feb 22 2013 - Updated Feb 23 2013 - 1 reports

Canaccord Capital Inc

NPS Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript

NPS Pharmaceuticals, Inc. ( NPSP ) Q4 2012 Earnings Call February 21, 2013 4:30 PM ET Executives Susan Mesco – Senior Director, IR and Corporate Communications Francois Nader – President and CEO Eric Pauwels – SVP and Chief Commercial Officer ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 22 2013]

Entities: NPS Pharmaceuticals Inc, Francois Nader, David Friedman, Pauwels, Canaccord Capital Inc

First reported Jan 03 2013 - Updated Jan 03 2013 - 1 reports

NPS Pharmaceuticals' CEO Discusses FDA Approval of Gattex (Transcript)

NPS Pharmaceuticals, Inc. ( NPSP ) Discussion on FDA Approval of Gattex Call January 2, 2013 5:00 PM ET Executives Susan Mesco – Senior Director, IR and Corporate Communications Francois Nader – President and CEO Eric Pauwels – SVP and Chief ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 03 2013]

Entities: NPS Pharmaceuticals Inc, GATTEX, Francois Nader, David Friedman

First reported Dec 28 2012 - Updated Dec 28 2012 - 1 reports

Why Pharma Is Easy Prey For Insider Trading

Over the past year, a growing number of insider trading cases involved information concerning drugs, devices and companies that develop them. But the recent case involving Sid Gilman, a leading Alzheimer’s expert and former University of Michigan neurology ... [Published Pharmalot - Dec 28 2012]

Entities: Insider Trading, Prey (video game), Garret FitzGerald

First reported Dec 26 2012 - Updated Dec 26 2012 - 1 reports

A Comprehensive Analysis Of NPS Pharmaceuticals

By Codespeed : In 2006, NPS Pharmaceuticals ( NPSP ) had found itself in big mess after its stock price dropped 37% on a single day after the FDA asked the company to run additional clinical trials on its upcoming drug for Osteoporosis. Cash reserves ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 26 2012]

Entities: NPS Pharmaceuticals Inc, Drugs, Francois Nader, GATTEX

More Content

sort by: Date \| Relevance
NPS Pharmaceuticals Q1 net loss decreases [Published Individual.com - 6 hours ago]
Vascular Files Patent Infringement Complaint Ag... [Published BioMedReports - May 17 2013]
NPS Pharmaceuticals CEO Dr. Francois Nader Reco... [Published Citybizlist - May 16 2013]
NPS Pharmaceuticals, Inc. President and CEO Rec... [Published BioSpace - May 16 2013]
NPS Pharmaceuticals President and CEO Dr. Franc... [Published Business Wire Health News - May 16 2013]
NPS Pharmaceuticals Posts First Quarter 2013 Fi... [Published Individual.com - May 14 2013]
NPS Pharmaceuticals' CEO Discusses Q1 2013 Resu... [Published Seeking Alpha - May 09 2013]
NPS begins to rack up sales of pricey SBS drug [Published FiercePharma - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published Freshnews.com - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published EON - May 09 2013]
NPS Pharmaceuticals Reports First Quarter 2013 ... [Published Yahoo! Finance - May 09 2013]
NPS Pharmaceuticals Among 100 Best Places to Wo... [Published Equities.com - May 08 2013]
Ernst & Young announces Entrepreneur Of The ... [Published SAP Developer's Journal - May 01 2013]
Ernst & Young announces Entrepreneur Of The Yea... [Published Individual.com - May 01 2013]
Ernst & Young announces Entrepreneur Of The Yea... [Published Street Insider - May 01 2013]
BioNJ To Host 2ND Annual Life Sciences Industry... [Published Business Wire - Apr 30 2013]
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP,... [Published Forbes.com - Apr 16 2013]
Deals of the Week Wants Cash on the Barrelhead [Published The IN VIVO Blog - Mar 22 2013]
NPS Pharmaceuticals and Takeda Revise Agreement... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 19 2013]
NPS Pharmaceuticals and Takeda Revise Agreement... [Published Yahoo! Finance - Mar 19 2013]
NPS Pharmaceuticals' CEO Presents at Barclays C... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 13 2013]
NPS Pharmaceuticals' CEO Discusses Q4 2012 Resu... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 22 2013]
NPS Pharmaceuticals Reports 2012 Financial Resu... [Published Stockwatch - Feb 21 2013]
BioNJ Installs New Chair, Members on its Board ... [Published Business Wire Science: Science News - Feb 13 2013]
BioNJ Installs New Chair, Members on its Board ... [Published Business Wire Health News - Feb 13 2013]
The Value Of A Pricey Orphan Drug: Nader Explains [Published Pharmalot - Feb 01 2013]
BioNJ Names NPS Pharmaceuticals’ President and ... [Published Business Wire Health News - Jan 07 2013]
NPS Pharmaceuticals' CEO Discusses FDA Approval... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 03 2013]
Why Pharma Is Easy Prey For Insider Trading [Published Pharmalot - Dec 28 2012]
A Comprehensive Analysis Of NPS Pharmaceuticals [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 26 2012]